Protara Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TARA research report →
Companywww.protaratx.com
Protara Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.
- CEO
- Jesse Shefferman
- IPO
- 2014
- Employees
- 28
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $183.69M
- P/E
- -3.22
- P/S
- 0.00
- P/B
- 1.13
- EV/EBITDA
- -2.47
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.70%
- ROIC
- -38.02%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-57,439,000 · -28.80%
- EPS
- $-1.34 · 38.25%
- Op Income
- $-64,549,000
- FCF YoY
- -57.39%
Performance & Tape
- 52W High
- $7.82
- 52W Low
- $2.77
- 50D MA
- $5.21
- 200D MA
- $5.14
- Beta
- 1.52
- Avg Volume
- 932.85K
Get TickerSpark's AI analysis on TARA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 8, 26 | Zummo Jacqueline | sell | 1,134 |
| Apr 1, 26 | Zummo Jacqueline | sell | 22,598 |
| Jan 26, 26 | Fry Hannah | other | 1,457 |
| Jan 26, 26 | Fabbio Patrick | other | 3,261 |
| Jan 26, 26 | Shefferman Jesse | other | 8,732 |
| Jan 26, 26 | Zummo Jacqueline | other | 3,724 |
| Jan 20, 26 | Shefferman Jesse | other | 16,322 |
| Jan 20, 26 | Fabbio Patrick | other | 3,063 |
| Jan 20, 26 | Zummo Jacqueline | other | 6,578 |
| Jan 20, 26 | Fry Hannah | other | 2,132 |
Our TARA Coverage
We haven't published any research on TARA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TARA Report →